Search Results - "Dousset, Lea"

NADPH Oxidase-1 Plays a Key Role in Keratinocyte Responses to UV Radiation and UVB-Induced Skin Carcinogenesis by Raad, Houssam, Serrano-Sanchez, Martin, Harfouche, Ghida, Mahfouf, Walid, Bortolotto, Doriane, Bergeron, Vanessa, Kasraian, Zeinab, Dousset, Lea, Hosseini, Mohsen, Taieb, Alain, Rezvani, Hamid Reza

“…The nicotinamide adenine dinucleotide phosphate oxidase (NOX) family enzymes are involved in several physiological functions. However, their roles in…”
Get full text

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study by Kostine, Marie, Rouxel, Léa, Barnetche, Thomas, Veillon, Rémi, Martin, Florent, Dutriaux, Caroline, Dousset, Léa, Pham-Ledard, Anne, Prey, Sorilla, Beylot-Barry, Marie, Daste, Amaury, Gross-Goupil, Marine, Lallier, Julie, Ravaud, Alain, Forcade, Edouard, Bannwarth, Bernard, Truchetet, Marie-Elise, Richez, Christophe, Mehsen, Nadia, Schaeverbeke, Thierry

“…To evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as…”
Get more information

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo by Larsabal, Maiana, MD, Marti, Aurélie, MD, Jacquemin, Clément, PhD, Rambert, Jérôme, PhD, Thiolat, Denis, BS, Dousset, Léa, MD, Taieb, Alain, MD, PhD, Dutriaux, Caroline, PhD, MD, Prey, Sorilla, MD, PhD, Boniface, Katia, PhD, Seneschal, Julien, MD, PhD

“…Background The use of anti-programmed cell death (PD)-1 therapies in metastatic tumors is associated with cutaneous side effects including vitiligo-like…”
Get full text

Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass by Kostine, Marie, Dousset, Léa, Schaeverbeke, Thierry

Get more information

Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events by Kostine, Marie, Mauric, Eleonora, Tison, Alice, Barnetche, Thomas, Barre, Aurélien, Nikolski, Macha, Rouxel, Léa, Dutriaux, Caroline, Dousset, Léa, Prey, Sorilla, Beylot-Barry, Marie, Seneschal, Julien, Veillon, Rémi, Vergnenegre, Charlotte, Daste, Amaury, Domblides, Charlotte, Sionneau, Baptiste, Gross-Goupil, Marine, Ravaud, Alain, Forcade, Edouard, Schaeverbeke, Thierry

“…As gut microbiota composition is an important determinant of response to immune checkpoint inhibitors (ICIs), we examined the effect of various co-medications…”
Get full text

Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II by Ferrer, Florent, Tetu, Pauline, Dousset, Léa, Lebbe, Céleste, Ciccolini, Joseph, Combarel, David, Meyer, Nicolas, Paci, Angelo, Bouchet, Stéphane

“…Real-life populations are more heterogeneous than those included in prospective clinical studies. In cancer patients, comorbidities and co-medications favor…”
Get full text

Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I by Combarel, David, Dousset, Léa, Bouchet, Stéphane, Ferrer, Florent, Tetu, Pauline, Lebbe, Céleste, Ciccolini, Joseph, Meyer, Nicolas, Paci, Angelo

“…A multitude of TKI has been developed and approved targeting various oncogenetic alterations. While these have provided improvements in efficacy compared with…”
Get full text

Assessment of Liquid Biopsy in Primary Cutaneous Diffuse Large B-Cell Lymphoma–Leg Type by Guicheney, Marie, Ducharme, Océane, Caumont, Charline, Gerard, Emilie, Dousset, Léa, Beylot-Barry, Marie, Merlio, Jean-Philippe, Gros, Audrey, Pham-Ledard, Anne

Get full text

Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma by Marescassier, Hélène, Dousset, Léa, Beylot-Barry, Marie, Célérier, Philippe, Vaillant, Loïc, Bedane, Christophe, Leclère, Franck, Wierzbicka-Hainaut, Ewa, Masson Regnault, Marie

“…Vismodegib has shown clinical efficacy in the management of locally advanced basal cell carcinomas (laBCC). However, non-response to vismodegib is observed in…”
Get more information

Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas by Schneider, Sophie, Ferte, Thomas, Ducharme, Océane, Dousset, Léa, Prey, Sorilla, Dutriaux, Caroline, Gerard, Emilie, Beylot-Barry, Marie, Pham-Ledard, Anne

“…Purpose Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in white-skinned populations. There is little information on the epidemiology…”
Get full text

Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma by Rousset, Marine, Dutriaux, Caroline, Bosco-Lévy, Pauline, Prey, Sorilla, Pham-Ledard, Anne, Dousset, Léa, Gérard, Emilie, Bouchet, Stephane, Canal-Raffin, Mireille, Titier, Karine, Molimard, Mathieu

“…Dabrafenib and trametinib bitherapy provides significant benefits in BRAFV600mut metastatic melanoma patients; however, adverse events (AE) occur, leading to…”
Get full text

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study by Manson, Guillaume, Maria, Alexandre Thibault Jacques, Poizeau, Florence, Danlos, François-Xavier, Kostine, Marie, Brosseau, Solenn, Aspeslagh, Sandrine, Du Rusquec, Pauline, Roger, Maxime, Pallix-Guyot, Maud, Ruivard, Marc, Dousset, Léa, Grignou, Laurianne, Psimaras, Dimitri, Pluvy, Johan, Quéré, Gilles, Grados, Franck, Duval, Fanny, Bourdain, Frederic, Maigne, Gwenola, Perrin, Julie, Godbert, Benoit, Taifas, Beatris Irina, Forestier, Alexandra, Voisin, Anne-Laure, Martin-Romano, Patricia, Baldini, Capucine, Marabelle, Aurélien, Massard, Christophe, Honnorat, Jérôme, Lambotte, Olivier, Michot, Jean-Marie

“…BackgroundParaneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1…”
Get full text

Giant syringocystadenocarcinoma papilliferum with conjunctival recurrence: Possible Schimmelpenning syndrome with postzygotic G13R HRAS and K601N BRAF signature by Dupont, Aurore, Vergara, Rémi, Pacaud, Alizé, Dequidt, Laure, Dutriaux, Caroline, Saunier, Valentine, Caumont, Charline, Jullie, Marie‐Laure, Taïeb, Alain, Morice‐Picard, Fanny, Dousset, Léa

Get full text

Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma by Valentin, Julie, Gérard, Emilie, Ferte, Thomas, Prey, Sorilla, Dousset, Léa, Dutriaux, Caroline, Beylot-Barry, Marie, Pham-Ledard, Anne

“…Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) mostly affects older and frail patients. Cemiplimab is an anti-PD1 antibody used in…”
Get full text

Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation by Hosseini, Mohsen, Dousset, Léa, Mahfouf, Walid, Serrano-Sanchez, Martin, Redonnet-Vernhet, Isabelle, Mesli, Samir, Kasraian, Zeinab, Obre, Emilie, Bonneu, Marc, Claverol, Stephane, Vlaski, Marija, Ivanovic, Zoran, Rachidi, Walid, Douki, Thierry, Taieb, Alain, Bouzier-Sore, Anne-Karine, Rossignol, Rodrigue, Rezvani, Hamid Reza

“…Although growing evidence indicates that bioenergetic metabolism plays an important role in the progression of tumorigenesis, little information is available…”
Get full text

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study by Valentin, Julie, Ferté, Thomas, Dorizy-Vuong, Valérie, Dousset, Léa, Prey, Sorilla, Dutriaux, Caroline, Pham-Ledard, Anne, Beylot-Barry, Marie, Gérard, Emilie

“…Objective. Anti-PD-1 has dramatically improved the survival of patients with advanced melanoma. However, there is a lack of data on maintenance of the response…”
Get full text

Radiation-induced Bullous Lichen Planus: An Isomorphic Manifestation of Radiotherapy by Cirotteau, Paul, Lucas, Philippine, Dousset, Léa, Cales, Valérie, Gilliot, Olivier, Jouary, Thomas

“…Abstract is missing (Short communication)…”
Get full text

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study by Dousset, Léa, Pacaud, Alize, Barnetche, Thomas, Kostine, Marie, Dutriaux, Caroline, Pham-Ledard, Anne, Beylot-Barry, Marie, Gérard, Emilie, Prey, Sorilla, Andreu, Nicolas, Boniface, Katia, Seneschal, Julien

“…Clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 (PD-1) remain unknown. To better characterize the occurrence of…”
Get full text

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy by Dousset, Léa, Poizeau, Florence, Robert, Caroline, Mansard, Sandrine, Mortier, Laurent, Caumont, Charline, Routier, Émilie, Dupuy, Alain, Rouanet, Jacques, Battistella, Maxime, Greliak, Anna, Cappellen, David, Galibert, Marie-Dominique, Allayous, Clara, Lespagnol, Alexandra, Gerard, Émilie, Kerneuzet, Inès, Roy, Séverine, Dutriaux, Caroline, Merlio, Jean-Philippe, Vergier, Beatrice, Schrock, Alexa B, Lee, Jessica, Ali, Siraj M, Kammerer-Jacquet, Solène-Florence, Lebbé, Céleste, Beylot-Barry, Marie, Boussemart, Lise

“…Emerging evidence suggests a correlation between the tumor mutational burden (TMB) and the response to programmed cell death-1 protein (PD-1) monotherapy…”
Get more information

Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma by Barailler, Héloïse, Salomon, Guillemette, Dutriaux, Caroline, Prey, Sorilla, Gérard, Emilie, Dousset, Léa, Mertens, Cécile, Beylot-Barry, Marie, Meyer, Nicolas, Pham-Ledard, Anne

Get full text